Vistagen Therapeutics Inc (VTGN)
4.37
-0.11
(-2.46%)
USD |
NASDAQ |
May 10, 16:00
4.37
0.00 (0.00%)
After-Hours: 20:00
Vistagen Therapeutics Research and Development Expense (Quarterly): 4.538M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.538M |
| September 30, 2023 | 3.851M |
| June 30, 2023 | 4.197M |
| March 31, 2023 | 9.337M |
| December 31, 2022 | 6.854M |
| September 30, 2022 | 12.89M |
| June 30, 2022 | 15.29M |
| March 31, 2022 | 12.23M |
| December 31, 2021 | 7.78M |
| September 30, 2021 | 9.936M |
| June 30, 2021 | 5.457M |
| March 31, 2021 | 4.340M |
| December 31, 2020 | 3.496M |
| September 30, 2020 | 2.358M |
| June 30, 2020 | 1.731M |
| March 31, 2020 | 1.841M |
| December 31, 2019 | 3.014M |
| September 30, 2019 | 4.205M |
| June 30, 2019 | 4.314M |
| March 31, 2019 | 3.758M |
| December 31, 2018 | 5.336M |
| September 30, 2018 | 5.261M |
| June 30, 2018 | 2.744M |
| March 31, 2018 | 2.638M |
| December 31, 2017 | 1.602M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.427M |
| June 30, 2017 | 1.096M |
| March 31, 2017 | 1.161M |
| December 31, 2016 | 1.611M |
| September 30, 2016 | 1.606M |
| June 30, 2016 | 0.8257M |
| March 31, 2016 | 1.097M |
| December 31, 2015 | 0.8063M |
| September 30, 2015 | 1.656M |
| June 30, 2015 | 0.3726M |
| March 31, 2015 | 0.9561M |
| December 31, 2014 | 0.4454M |
| September 30, 2014 | 0.5576M |
| June 30, 2014 | 0.4736M |
| March 31, 2014 | 0.5645M |
| December 31, 2013 | 0.5513M |
| September 30, 2013 | 0.6693M |
| June 30, 2013 | 0.6955M |
| March 31, 2013 | 0.3386M |
| December 31, 2012 | 1.120M |
| September 30, 2012 | 1.106M |
| June 30, 2012 | 0.8663M |
| March 31, 2012 | 1.828M |
| December 31, 2011 | 1.306M |
| September 30, 2011 | 1.228M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.731M
Minimum
Jun 2020
15.29M
Maximum
Jun 2022
6.193M
Average
4.340M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Ardelyx Inc | 10.58M |
| Axsome Therapeutics Inc | 36.83M |
| Vir Biotechnology Inc | 100.12M |
| Immuneering Corp | 11.20M |
| NovaBay Pharmaceuticals Inc | 0.004M |